Donepezil hydrochloride (sold most famously as Aricept) is a prescription medication that slows the breakdown of acetylcholine, a brain chemical critical for memory and learning. It was approved for Alzheimer’s disease in 1996 and remains one of the most widely prescribed dementia medications worldwide. Donepezil does not cure or halt Alzheimer’s, but across dozens of clinical trials it has consistently shown modest improvements in cognition and daily functioning, and it can delay the point at which a person needs full-time care.
How Donepezil Works in the Brain
In Alzheimer’s disease, neurons that produce acetylcholine progressively die off, leaving the brain short of a neurotransmitter it needs for attention, memory formation, and communication between nerve cells. Donepezil blocks acetylcholinesterase, the enzyme that normally breaks acetylcholine down after it has done its job. By slowing that breakdown, more acetylcholine stays available in the gaps between neurons, partially compensating for the loss of the cells that make it.1PubMed. Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature The drug is a reversible inhibitor, meaning it latches onto the enzyme temporarily rather than destroying it, and it works through both competitive and noncompetitive binding.
This cholinergic boost accounts for the drug’s primary effects, but it is not the whole story. Brain-imaging research using PET scans has shown that at normal therapeutic doses, donepezil also binds to sigma-1 receptors in the living human brain.2International Journal of Neuropsychopharmacology. High occupancy of σ1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503 Sigma-1 receptors are involved in nerve-cell protection and the regulation of calcium signaling. Whether this secondary action meaningfully contributes to the clinical benefits patients experience is still an open question, but it is one reason researchers have explored donepezil for conditions beyond Alzheimer’s.3PubMed Central. Donepezil Beyond Alzheimer’s Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
Cognitive Benefits in Alzheimer’s Disease
The evidence base for donepezil in Alzheimer’s is substantial. A Cochrane systematic review pooling data from multiple large trials found that after about six months of treatment, people taking donepezil scored meaningfully better than those on placebo on standard cognitive tests. On the most commonly used scale for measuring Alzheimer’s-related cognitive decline (the ADAS-Cog), the average advantage was roughly 2.7 points, and on the Mini-Mental State Examination it was about 1 point.4PubMed Central. Donepezil for dementia due to Alzheimer’s disease Those numbers sound small in isolation, but in a disease where cognition only moves in one direction, holding relatively steady for six months while a placebo group declines is a real gain.
The benefits appear to be more pronounced when treatment begins early. A randomized trial focused specifically on early-stage Alzheimer’s found that improvements on cognitive tests appeared as early as six weeks after starting donepezil, and at 24 weeks the drug-placebo difference on the MMSE was about 1.8 points. Perhaps more telling, at least 70% of patients on donepezil showed no cognitive worsening during the study period, compared with 47% of those on placebo.5JAMA Neurology. Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial A separate study comparing mild versus moderate Alzheimer’s confirmed that patients with milder disease got more out of treatment, particularly in memory-related domains.6PubMed. Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease: implications for early diagnosis and treatment
The Higher-Dose Option for More Advanced Disease
Standard donepezil dosing starts at 5 mg daily and is typically increased to 10 mg after a month or so. For people with moderate to severe Alzheimer’s, a 23 mg daily tablet was developed. In a 24-week head-to-head trial comparing 23 mg to 10 mg in patients already on the lower dose, the higher dose produced a statistically significant additional improvement on a cognitive assessment designed for more advanced disease.7PubMed Central. Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer’s Disease: A 24-Week, Randomized, Double-Blind Study A deeper look at the data revealed that the cognitive advantages of the 23 mg dose were greatest in patients with the lowest baseline scores, particularly in language, memory, and visuospatial ability.8PubMed Central. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer’s disease: evaluating the impact of baseline severity
The trade-off is tolerability. The 23 mg tablet tends to cause more nausea, vomiting, and diarrhea than the 10 mg dose, so doctors usually reserve it for patients who have been stable on 10 mg for at least three months and whose disease has progressed enough that the additional cognitive benefit justifies the extra side effects.
How Donepezil Compares to Other Cholinesterase Inhibitors
Three cholinesterase inhibitors are commonly prescribed for Alzheimer’s: donepezil, rivastigmine, and galantamine. Patients and families often want to know whether one is clearly better than the others. The honest answer is that the differences are modest. A systematic review of head-to-head comparisons found no strong evidence favoring any single drug over the others on cognition.9PubMed. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease
A large network meta-analysis of 41 trials did rank galantamine at 24-32 mg and donepezil at 10 mg among the most effective agents for cognition in mild to moderate Alzheimer’s, with rivastigmine’s transdermal patch performing best for function and global clinical impression.10PubMed Central. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials In practice, the choice often comes down to side-effect profile and convenience. Donepezil’s once-daily dosing and relatively mild gastrointestinal effects have made it the default first-line option in many clinical settings, while rivastigmine’s patch form appeals to patients who struggle with oral medications.
Adding Memantine to Donepezil
For people with moderate to severe Alzheimer’s, adding memantine (a drug that works through a completely different mechanism, blocking excessive glutamate signaling) to ongoing donepezil therapy is a common strategy. The evidence supports it. In pooled analyses of moderate-to-severe patients, adding memantine to donepezil produced better outcomes in cognition, daily function, and overall clinical status than donepezil alone. Fewer patients on the combination showed marked clinical worsening: roughly 9% versus 20% in the donepezil-plus-placebo group.11PubMed Central. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy
A separate analysis looking at cumulative benefits over time found that the combination had an additive effect, meaning each drug contributed something the other did not, rather than one simply boosting the other’s action.12PubMed Central. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis The combination also outperformed memantine alone by a wider margin than it outperformed donepezil alone, which makes practical sense: memantine on its own has smaller cognitive effects than a cholinesterase inhibitor.
Common Side Effects and How to Manage Them
Because donepezil increases acetylcholine activity throughout the body, not just in the brain, its side effects are largely what you would expect from a cholinergic boost. The most common complaints are nausea, diarrhea, loss of appetite, and vomiting.13PubMed. Donepezil: a clinical review of current and emerging indications These tend to cluster around dose initiation or increases and often settle down within a few weeks.14American Journal of Health-System Pharmacy. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease Insomnia, muscle cramps, and fatigue round out the list of commonly reported issues.
Compared with the other cholinesterase inhibitors, donepezil tends to cause fewer gastrointestinal problems. Its selectivity for acetylcholinesterase in the brain rather than the less-selective peripheral enzyme (butyrylcholinesterase) likely explains the difference.15PubMed Central. The safety and tolerability of donepezil in patients with Alzheimer’s disease That said, moving from 10 mg to 23 mg substantially raises the incidence of gut-related side effects, which is why many doctors approach the higher dose cautiously.
One side effect worth special attention: vivid nightmares. A study of patients with Alzheimer’s found a clear link between nightmares and taking donepezil in the evening. When those same patients switched to a morning dose, the nightmares stopped.16PubMed. Nightmares in patients with Alzheimer’s disease caused by donepezil. Therapeutic effect depends on the time of intake The likely explanation is that donepezil enhances activity in the visual cortex during REM sleep. If you or someone you care for develops disturbing dreams after starting donepezil, switching the dose to the morning is a simple fix worth trying before considering a medication change.
Heart Rhythm Concerns
One area where the evidence is genuinely mixed involves the heart. Donepezil can, through its cholinergic effects, slow the heart rate modestly. More worrying, some studies have found that long-term use can prolong the QT interval on an electrocardiogram, which in theory raises the risk of a dangerous heart-rhythm disturbance. One study of patients on long-term donepezil reported significant QT prolongation, with about 14% of patients developing an arrhythmogenic-risk pattern.17PubMed Central. Donepezil-induced QTc prolongation: A case report
However, other research found no significant changes in heart rhythm, blood pressure, or ECG parameters in elderly Alzheimer’s patients taking donepezil at standard doses.18Internal Medicine. Cardiac Safety of Donepezil in Elderly Patients with Alzheimer Disease The risk appears to be highest in people who already have cardiac conduction problems, are on other QT-prolonging medications, or have electrolyte imbalances. For most patients, the cardiac risk at standard doses is low, but periodic ECG monitoring is a reasonable precaution, especially when doses are increased or when other medications are added.
Uses Beyond Alzheimer’s Disease
Donepezil’s approval is for Alzheimer’s, but doctors frequently prescribe it off-label for other forms of dementia, and the evidence for some of these uses is reasonably strong.
Dementia with Lewy Bodies
In dementia with Lewy bodies (DLB), a condition that shares features with both Alzheimer’s and Parkinson’s, donepezil has shown particularly encouraging results. A randomized trial found that 5 mg and 10 mg doses were significantly better than placebo on cognitive and global measures, with the 5 mg dose actually producing the largest MMSE improvement (about 3.8 points over placebo). Behavioral symptoms and caregiver burden also improved, especially at the 10 mg dose.19PubMed Central. Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial A follow-up open-label extension showed that cognitive benefits persisted for at least a year, and patients who had been on placebo improved once they started active treatment.20PubMed Central. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial A confirmatory trial supported the 10 mg dose’s cognitive benefits, though its effects on behavioral symptoms were less clear-cut in that particular study.21PubMed Central. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
Vascular Dementia
Two large trials tested donepezil in people with cognitive decline from vascular disease (strokes or small-vessel disease in the brain). Both showed that donepezil at 5 or 10 mg daily produced significantly better cognitive scores than placebo at 12 and 24 weeks.22PubMed Central. Donepezil for vascular cognitive impairment However, a separate trial in patients with CADASIL, a specific hereditary form of small-vessel disease, found no effect on the primary cognitive endpoint, though some measures of executive function did improve.23The Lancet Neurology. Donepezil in CADASIL: a randomised, placebo-controlled trial The takeaway is that donepezil may help cognition in vascular dementia broadly, but not all vascular conditions respond the same way.
What Happens When You Stop Donepezil
Discontinuation is a question families face eventually, especially as dementia advances and the practical benefits become harder to see. The evidence here is sobering. A Cochrane review of discontinuation studies found that stopping a cholinesterase inhibitor was associated with worse cognitive function in the short term and likely in the medium term as well.24Cochrane Database of Systematic Reviews. Withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia Data from one longer-term study suggested that the cognitive cost of stopping was about 2 points on the MMSE at 12 months, a clinically meaningful difference at that stage of disease.
In a major trial of moderate to severe Alzheimer’s patients, discontinuing donepezil more than doubled the risk of nursing home placement in the first year compared with continuing it.25The Lancet. Continuing or stopping donepezil and memantine in moderate to severe Alzheimer’s disease (DOMINO-AD): a randomised, double-blind, placebo-controlled trial The risk of abrupt withdrawal seems especially acute in patients with Lewy body dementia or Parkinson’s-related dementia, where sudden discontinuation can trigger sharp cognitive and behavioral deterioration.26PubMed. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia Case reports have documented delirium-like withdrawal states.27PubMed Central. Withdrawal syndrome after donepezil cessation in a patient with dementia If discontinuation is being considered, gradual tapering and close monitoring are standard advice.
Delaying Nursing Home Placement and Reducing Caregiver Burden
Beyond what shows up on a cognitive test score, families want to know whether donepezil changes anything that matters in daily life. Two findings stand out. First, an observational study found that sustained donepezil use at an effective dose for at least 9 to 12 months was associated with a delay in nursing home placement of roughly 17 to 21 months.28PubMed. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease That is not a small number. Even accounting for the limitations of observational data (sicker patients may stop treatment earlier, skewing results), the effect on institutional care timing has been one of the strongest practical arguments for maintaining treatment.
Second, donepezil meaningfully affects how much time family caregivers spend on care. Over one year, caregivers of patients on placebo were spending nearly two additional hours per day compared to baseline, while caregivers of donepezil-treated patients saw their time burden increase by only about 40 minutes. That gap of roughly an hour a day was statistically significant and has real implications for caregiver well-being and burnout.29PubMed. Impact of donepezil treatment for Alzheimer’s disease on caregiver time
Why Some People Respond Better Than Others
Not everyone benefits equally from donepezil, and genetics plays a role. Donepezil is broken down in the liver primarily by the CYP3A4 and CYP2D6 enzymes.30PubMed. Metabolic Activation and Cytotoxicity of Donepezil Induced by CYP3A4 People carry different versions of the genes encoding these enzymes, which affects how quickly they clear the drug from their bodies. A meta-analysis found that one specific CYP2D6 variant (the G allele at rs1080985) was associated with a significantly higher risk of poor treatment response, and that this risk was amplified in people who also carried the APOE-ε4 allele, the well-known genetic risk factor for Alzheimer’s itself.31PubMed. Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis Interestingly, APOE status alone did not predict donepezil response; it was the combination of genetic variants that mattered.
Pharmacogenomic testing for CYP2D6 is commercially available but is not yet part of routine clinical practice for donepezil prescribing. As the field matures, there is a reasonable chance that genetic profiling will help doctors predict who will benefit most and who might need a different approach from the start.
Transdermal Patches and Newer Formulations
Oral donepezil’s biggest practical drawback is that it can cause nausea and stomach upset, especially during dose increases. Because swallowing a pill sends the drug straight through the digestive tract, gut-related side effects are almost baked into the design. Transdermal patches offer an alternative route that bypasses the stomach entirely.32PubMed Central. Transdermal donepezil on the treatment of Alzheimer’s disease
A pharmacokinetic comparison found that donepezil patches delivered steadier blood levels with smaller peaks and troughs than daily oral doses, and were associated with fewer gastrointestinal and central-nervous-system side effects like dizziness and drowsiness. Patches applied once weekly maintained more consistent drug exposure than daily pills.33PubMed Central. Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil For patients who struggle with daily pill-taking or whose caregivers manage medications, a weekly patch could also simplify treatment. Availability varies by country, but patch formulations are gradually gaining ground.
What Happens in an Overdose
Donepezil has a wide therapeutic margin at standard doses, but accidental or intentional overdose can be dangerous. Too much acetylcholinesterase inhibition floods the body with acetylcholine, producing a cholinergic crisis: severe nausea, vomiting, excessive salivation, sweating, slowed heart rate, and in serious cases, muscle weakness or seizures.34PubMed. Cholinergic symptoms and QTc prolongation following donepezil overdose The cardiac effects can be particularly concerning, with QT prolongation and heart-rhythm abnormalities reported after large ingestions. The presentation can mimic a beta-blocker overdose, which creates a diagnostic trap in the emergency department.35PubMed Central. Suspected donepezil toxicity: A case report
There is no specific antidote for donepezil overdose, though atropine (a cholinergic blocker) is sometimes used for severe bradycardia. Treatment is mainly supportive, with careful cardiac monitoring. Donepezil’s long half-life, around 70 hours, means symptoms can persist or re-emerge well after the ingestion, so extended observation is important. For households with dementia patients, pill organizers and caregiver oversight of medication administration help prevent accidental double-dosing.
The Discovery Behind the Drug
Donepezil’s origin story is an unusually tidy example of medicinal chemistry iteration. Japanese researchers at Eisai began with a random compound screen that turned up an N-benzylpiperazine derivative with cholinergic activity in rats. Through a series of deliberate chemical modifications, swapping one ring structure for another, replacing an amide group with a ketone, and then creating a cyclic variant, the team arrived at an indanone-based compound that combined strong acetylcholinesterase inhibition with favorable drug-like properties.36PubMed. Discovery and development of donepezil hydrochloride for the treatment of Alzheimer’s disease That compound became donepezil hydrochloride, branded as Aricept. The step-by-step optimization is part of why donepezil ended up more selective for brain acetylcholinesterase than older, less refined inhibitors, a feature that translates directly into its relatively clean side-effect profile at standard doses.